Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Irma Meijerman

Showing results (21-30 of 27) with videos related to

Pageof 3
Sort By:
You have reached the last page of results.This site can display upto 27 results.
Anti-Cancer Drugs|September 16, 2005
In-vitro cytotoxicity of ET-743 (Trabectedin, Yondelis), a marine anti-cancer drug, in the Hep G2 cell line: influence of cytochrome P450 and phase II inhibition, and cytochrome P450 inductionEsther F A Brandon, Irma Meijerman, Joyce S Klijn, et al.
American Journal of Pharmacogenomics : Genomics-Related Research in Drug Development and Clinical Practice|April 9, 2005
Detection of single nucleotide polymorphisms in the ABCG2 gene in a Dutch populationTessa M Bosch, Linda M Kjellberg, Anja Bouwers, et al.
Investigational New Drugs|April 25, 2006
In vitro characterization of the human biotransformation pathways of aplidine, a novel marine anti-cancer drugEsther F A Brandon, Rolf W Sparidans, Ronald D van Ooijen, et al.
British Journal of Clinical Pharmacology|May 25, 2013
The effect of Echinacea purpurea on the pharmacokinetics of docetaxelAndrew K L Goey, Irma Meijerman, Hilde Rosing, et al.
The Journal of Pharmacy and Pharmacology|January 8, 2014
The effect of complementary and alternative medicines on CYP3A4-mediated metabolism of three different substrates: 7-benzyloxy-4-trifluoromethyl-coumarin, midazolam and docetaxelKim D Mooiman, Roel F Maas-Bakker, Jeroen J M A Hendrikx, et al.
Clinical and Translational Allergy|November 25, 2023
A robust mRNA signature obtained via recursive ensemble feature selection predicts the responsiveness of omalizumab in moderate-to-severe asthmaSarah Kidwai, Pietro Barbiero, Irma Meijerman, et al.
Toxicology and Applied Pharmacology|June 25, 2005
Validation of in vitro cell models used in drug metabolism and transport studies; genotyping of cytochrome P450, phase II enzymes and drug transporter polymorphisms in the human hepatoma (HepG2), ovarian carcinoma (IGROV-1) and colon carcinoma (CaCo-2, LS180) cell linesEsther F A Brandon, Tessa M Bosch, Maarten J Deenen, et al.
Pageof 3

Showing results (21-30 of 27) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 27 results.
Anti-Cancer Drugs|September 16, 2005
In-vitro cytotoxicity of ET-743 (Trabectedin, Yondelis), a marine anti-cancer drug, in the Hep G2 cell line: influence of cytochrome P450 and phase II inhibition, and cytochrome P450 inductionEsther F A Brandon, Irma Meijerman, Joyce S Klijn, et al.
American Journal of Pharmacogenomics : Genomics-Related Research in Drug Development and Clinical Practice|April 9, 2005
Detection of single nucleotide polymorphisms in the ABCG2 gene in a Dutch populationTessa M Bosch, Linda M Kjellberg, Anja Bouwers, et al.
Investigational New Drugs|April 25, 2006
In vitro characterization of the human biotransformation pathways of aplidine, a novel marine anti-cancer drugEsther F A Brandon, Rolf W Sparidans, Ronald D van Ooijen, et al.
British Journal of Clinical Pharmacology|May 25, 2013
The effect of Echinacea purpurea on the pharmacokinetics of docetaxelAndrew K L Goey, Irma Meijerman, Hilde Rosing, et al.
The Journal of Pharmacy and Pharmacology|January 8, 2014
The effect of complementary and alternative medicines on CYP3A4-mediated metabolism of three different substrates: 7-benzyloxy-4-trifluoromethyl-coumarin, midazolam and docetaxelKim D Mooiman, Roel F Maas-Bakker, Jeroen J M A Hendrikx, et al.
Clinical and Translational Allergy|November 25, 2023
A robust mRNA signature obtained via recursive ensemble feature selection predicts the responsiveness of omalizumab in moderate-to-severe asthmaSarah Kidwai, Pietro Barbiero, Irma Meijerman, et al.
Toxicology and Applied Pharmacology|June 25, 2005
Validation of in vitro cell models used in drug metabolism and transport studies; genotyping of cytochrome P450, phase II enzymes and drug transporter polymorphisms in the human hepatoma (HepG2), ovarian carcinoma (IGROV-1) and colon carcinoma (CaCo-2, LS180) cell linesEsther F A Brandon, Tessa M Bosch, Maarten J Deenen, et al.
Pageof 3